Valuation: Moderna, Inc.

Market Cap 31.65B 27.76B 25.63B 23.68B 44.89B 3,031B 45.79B 308B 120B 1,483B 119B 116B 5,148B P/E 2026 *
-9.21x
P/E 2027 * -16.8x
Enterprise Value 28.25B 24.77B 22.87B 21.14B 40.06B 2,705B 40.86B 275B 107B 1,324B 106B 104B 4,594B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 11.6x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-6.93%
1 week+3.30%
Current month+6.94%
1 month+57.33%
3 months+43.74%
6 months+121.18%
Current year+153.95%
1 week 73.68
Extreme 73.68
85.6
1 month 45.4
Extreme 45.4
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
07-02Fiscal year

Chief Financial Officer

3,607 0.0009%
06-15Fiscal year

Chairperson

160,008 0.0403%
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-6.88%+3.30%+130.15%-39.16% 31.65B
-1.77%+6.11%+21.02%-5.75% 68.8B
-2.01%-3.57%+46.21%+217.06% 55.21B
-4.15%+36.30%+36.30%+36.30% 43.46B
+0.27%+8.33%-49.87%-53.43% 41.18B
-1.66%-3.87%+49.95%-28.40% 30.37B
-1.05%+2.50%+72.38%+88.48% 23.58B
-1.15%+8.29%+4.42%+184.96% 19.33B
-1.33%+1.11%+66.11%+131.83% 17.16B
-0.71%+3.86%+79.21%+345.85% 15.27B
Average -2.06%+3.83%+45.59%+87.77% 34.6B
Weighted average by Cap. -2.18%+3.59%+38.42%+63.78%

Financials

2026 *2027 *
Net sales 2.09B 1.84B 1.7B 1.57B 2.97B 200B 3.03B 20.38B 7.92B 98.1B 7.86B 7.69B 341B 2.55B 2.24B 2.06B 1.91B 3.62B 244B 3.69B 24.82B 9.64B 119B 9.58B 9.37B 415B
Net income -3.41B -2.99B -2.76B -2.55B -4.84B -327B -4.93B -33.2B -12.9B -160B -12.81B -12.53B -555B -1.85B -1.62B -1.5B -1.38B -2.62B -177B -2.68B -18.01B -7B -86.7B -6.95B -6.8B -301B
Net Debt -3.41B -2.99B -2.76B -2.55B -4.83B -326B -4.93B -33.16B -12.88B -160B -12.79B -12.51B -554B -2.05B -1.8B -1.66B -1.54B -2.91B -197B -2.97B -19.99B -7.77B -96.21B -7.71B -7.54B -334B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
08/07/26 $74.89 -6.12% 4,124,229
07/07/26 $79.77 -2.48% 8,688,340
06/07/26 $81.80 +2.56% 17,296,875
02/07/26 $79.76 +10.01% 14,111,998
01/07/26 $72.50 +3.53% 9,275,292
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
79.77USD
Average target price
47.89USD
Spread / Average Target
-39.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock